157.21

0.76% -1.21

After Hours: 158.00 0.79 +0.50%

Neurocrine Biosciences Inc (NBIX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Neurocrine Biosciences Inc stock is traded at $157.21, with a volume of 1.13M. It is down -0.76% in the last 24 hours and up +17.98% over the past month. Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Previous Close:

$158.42

Open:

$158.7

24h Volume:

1.13M

Relative Volume:

0.93

Market Cap:

$15.81B

Revenue:

$2.86B

Net Income/Loss:

$478.60M

P/E Ratio:

33.68

EPS:

4.6676

Net Cash Flow:

$748.70M

1W Performance:

+4.40%

1M Performance:

+17.98%

6M Performance:

+13.40%

1Y Performance:

+29.90%

1-Day Range:

$156.09

$159.76

1-Week Range:

$150.82

$162.39

52-Week Range:

$117.59

$162.39

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name

Neurocrine Biosciences Inc

Sector

Healthcare (1109)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

(858) 617-7600

Address

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Employee

2,000

Twitter

Next Earnings Date

2026-05-05

Latest SEC Filings

NBIX's Discussions on Twitter

Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NBIX Neurocrine Biosciences Inc	157.21	15.93B	2.86B	478.60M	748.70M	4.6676
TAK Takeda Pharmaceutical Co Adr	16.57	52.48B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.17	39.72B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.03	39.93B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	77.72	31.12B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	566.99	24.13B	3.17B	1.29B	1.01B	27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-21-25	Initiated	Citigroup	Buy
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Initiated	Goldman	Buy
Apr-15-25	Upgrade	Needham	Hold → Buy
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-11-25	Initiated	Deutsche Bank	Hold
Oct-10-24	Resumed	Raymond James	Outperform
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-13-23	Resumed	Citigroup	Neutral
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Aug-21-23	Reiterated	Mizuho	Neutral
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform
May-04-23	Upgrade	Guggenheim	Neutral → Buy
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-22	Initiated	UBS	Buy
Sep-26-22	Initiated	Wells Fargo	Equal Weight
Jun-06-22	Resumed	Jefferies	Buy
Mar-03-22	Downgrade	Piper Sandler	Overweight → Neutral
Feb-25-22	Upgrade	Goldman	Neutral → Buy
Jan-18-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-19-21	Initiated	BMO Capital Markets	Underperform
Nov-17-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Aug-06-21	Downgrade	Canaccord Genuity	Buy → Hold
May-18-21	Resumed	Goldman	Neutral
May-06-21	Upgrade	Barclays	Equal Weight → Overweight
Feb-02-21	Initiated	Raymond James	Outperform
Sep-30-20	Initiated	The Benchmark Company	Hold
Aug-04-20	Downgrade	JP Morgan	Overweight → Neutral
Jun-29-20	Downgrade	Goldman	Buy → Neutral
Jun-09-20	Initiated	Wedbush	Outperform
Mar-06-20	Initiated	Citigroup	Buy
Feb-27-20	Initiated	Barclays	Equal Weight
Feb-24-20	Initiated	William Blair	Outperform
Feb-06-20	Initiated	Mizuho	Neutral
Feb-05-20	Reiterated	H.C. Wainwright	Buy
Dec-13-19	Downgrade	Credit Suisse	Outperform → Neutral
Aug-07-19	Initiated	RBC Capital Mkts	Outperform
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-05-19	Initiated	Guggenheim	Neutral
May-21-19	Initiated	Credit Suisse	Outperform
Apr-22-19	Upgrade	JP Morgan	Neutral → Overweight
Apr-12-19	Initiated	Evercore ISI	Outperform
Feb-06-19	Reiterated	BofA/Merrill	Buy
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Dec-13-18	Initiated	Goldman	Buy
Nov-21-18	Initiated	Canaccord Genuity	Buy

View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

06:22 AM

Neurocrine presents real-world data on tardive dyskinesia drug - Investing.com UK

06:22 AM

05:55 AM

Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock - Investing.com

05:55 AM

05:50 AM

Neurocrine (NBIX) director sells 15,000 shares under 10b5-1 plan - Stock Titan

05:50 AM

04:30 AM

Neurocrine presents real-world data on tardive dyskinesia drug By Investing.com - Investing.com Australia

04:30 AM

04:08 AM

Neurocrine presents data on INGREZZA treatment for mild tardive dyskinesia - StreetInsider

04:08 AM

04:05 AM

Survey: 'mild' movement disorder disrupts life, most improve on INGREZZA - Stock Titan

04:05 AM

02:21 AM

Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK

02:21 AM

02:01 AM

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma

02:01 AM

01:02 AM

Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo

01:02 AM

10:32 AM

Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart

10:32 AM

10:30 AM

Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart

10:30 AM

10:02 AM

Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio - citybiz

10:02 AM

09:58 AM

Neurocrine Biosciences completes $2.9 billion Soleno acquisition By Investing.com - Investing.com Australia

09:58 AM

09:51 AM

Neurocrine Biosciences completes acquisition of Soleno Therapeutics - marketscreener.com

09:51 AM

09:41 AM

Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq - Investing.com

09:41 AM

09:26 AM

Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics - TradingView

09:26 AM

09:24 AM

Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal - Stock Titan

09:24 AM

09:11 AM

Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger - Stock Titan

09:11 AM

09:04 AM

Neurocrine Biosciences (NASDAQ: NBIX) completes $2.9B Soleno acquisition - Stock Titan

09:04 AM

Neurocrine completes Soleno buyout (NASDAQ: SLNO) at $53.00 per share - Stock Titan

09:04 AM

08:57 AM

Neurocrine (SLNO) completes tender offer; ~46.36M Soleno shares tendered - Stock Titan

08:57 AM

08:46 AM

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - ChartMill

08:46 AM

06:03 AM

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference - Yahoo Finance

06:03 AM

12:30 PM

Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN

12:30 PM

May 17, 2026

Neurocrine Biosciences stock (US64125C1099): momentum after strong run in May and growing neuroscien - AD HOC NEWS

May 17, 2026

May 15, 2026

[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan

May 15, 2026

NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill

May 15, 2026

May 14, 2026

Neurocrine Biosciences director Norwalk sells $590,601 in stock By Investing.com - Investing.com Canada

May 14, 2026

Neurocrine Biosciences director Norwalk sells $590,601 in stock - Investing.com

May 14, 2026

Neurocrine (NBIX) director pre-plans sale of 3,810 shares via 10b5-1 plan - Stock Titan

May 14, 2026

Neurocrine Biosciences stock (US64125C1099): Recent clinical trial advancements and market position - AD HOC NEWS

May 14, 2026

May 13, 2026

Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN

May 13, 2026

Neurocrine Biosciences stock hits all-time high at 160.31 USD By Investing.com - Investing.com Nigeria

May 13, 2026

A Look at Neurocrine Biosciences Inc (NBIX) After 3.5% Gain -- G - GuruFocus

May 13, 2026

Neurocrine Biosciences stock hits all-time high at 160.31 USD - Investing.com

May 13, 2026

Neurocrine Biosciences (NBIX) Valuation After Strong Q1 2026 Results And New CRENESSITY And Obesity Pipeline Updates - simplywall.st

May 13, 2026

May 12, 2026

Number of shareholders of Neurocrine Biosciences, Inc. – MIL:1NBIX - TradingView

May 12, 2026

Neurocrine Biosciences stock (US64125C1099): Q1 2026 earnings beat with $815M revenue - AD HOC NEWS

May 12, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Screens as a Peter Lynch-Style GARP Opportunity - ChartMill

May 12, 2026

Neurocrine stock soars 61% after InvestingPro Fair Value signal By Investing.com - Investing.com Canada

May 12, 2026

May 11, 2026

Neurocrine Biosciences (NBIX) Is Up 13.6% After Q1 Beat And New CRENESSITY Data ReleaseHas The Bull Case Changed? - simplywall.st

May 11, 2026

Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat expectations By Investing.com - Investing.com South Africa

May 11, 2026

Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat expectations - Investing.com

May 11, 2026

RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $180 - Moomoo

May 11, 2026